17-beta-estradiol therapy lessens angin in postmenopausal women with syndrome X

Objectives. We sought to investigate the hypothesis that estrogen replacement therapy ameliorates symptoms in postmenopausal women with syndrome X. Background. Syndrome X (angin pectoris, positive findings on exercise electrocardiography and normal results on coronary angiography) frequently occurs in menopausal women. This observation, in conjuction with the known vasoactive properties of estrogens, suggests that estrogen depletion may contribute to the pathogenesis of syndrome X in some women. Methods. Twenty-five postmenopausal patients with syndrome X completed double-blind, placebo-controlled study of the effect of 17-beta-estradiol cutaneous patches (100 μg/24 h) on the frequency of chest pain and on exercise tolerance. Patients were randomly assigned to receive either placebo or 17-beta-estradiol patches for 8 weeks and were then crossed over to the other treatment. Results. During the placebo phase, patients had mean of 7.3 episodes of chest pain/10 days. reduction to 3.7 episodes/10 days was observed during the 17-beta-estradiol phase (p < 0.05). No significant differences were observed between the effects of 17-beta-estradiol and placebo on exercise duration or the results of other cardiologic investigations. Conclusions. Estrogen replacement reduces the frequency of chest pain and may be useful new therapeutic option for treating postmenopausal women with syndrome X.